STOCKHOLM--(BUSINESS WIRE)--Regulatory News:
In November 2013, BioGaia’s (STO:BIOGB) board of directors resolved to invest in a first phase of a project which aims at developing a prophylactic drug against necrotizing enterocolitis (NEC), which affects premature babies. BioGaia has, until 31 May 2015, provided financing of SEK 24 million to the project, of the total resolved amount of approximately SEK 47 million.
Help employers find you! Check out all the jobs and post your resume.
